MARKET

TRDA

TRDA

Entrada Therapeutics, Inc.
NASDAQ
7.00
+0.16
+2.34%
Pre Market: 6.85 -0.15 -2.14% 06:01 05/12 EDT
OPEN
6.96
PREV CLOSE
6.84
HIGH
7.36
LOW
6.82
VOLUME
33
TURNOVER
0
52 WEEK HIGH
16.45
52 WEEK LOW
4.930
MARKET CAP
271.74M
P/E (TTM)
-1.7510
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TRDA last week (0504-0508)?
Weekly Report · 1d ago
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
NASDAQ · 3d ago
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Entrada Therapeutics Inc (TRDA) and Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks · 3d ago
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Benzinga · 3d ago
Entrada Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral
Benzinga · 3d ago
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 4d ago
More
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.

Webull offers Entrada Therapeutics Inc stock information, including NASDAQ: TRDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRDA stock methods without spending real money on the virtual paper trading platform.